VEGF-A and the Induction of Pathological Angiogenesis
- 1 February 2007
- journal article
- review article
- Published by Annual Reviews in Annual Review Of Pathology-Mechanisms Of Disease
- Vol. 2 (1), 251-275
- https://doi.org/10.1146/annurev.pathol.2.010506.134925
Abstract
Tumors, wounds, and chronic inflammatory disorders generate a new vascular supply by a process known as pathological angiogenesis. Whereas formation of the normal blood vasculature requires the interaction of many different agonists and inhibitors, including vascular endothelial growth factor-A (VEGF-A) and other members of the vascular permeability factor/VEGF family, pathological angiogenesis is a cruder, simpler process that can be replicated by a single VEGF-A isoform, VEGF-A164/5. VEGF-A164/5induces the formation of several distinctly different types of new blood vessels that differ from normal blood vessels with respect to organization, structure, and function. Elucidating the properties of these new vessels has led to a better understanding of angiogenesis and will hopefully lead to new approaches to antiangiogenic therapy.Keywords
This publication has 108 references indexed in Scilit:
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006
- Neuropilins in neoplasms: Expression, regulation, and functionExperimental Cell Research, 2006
- Neuronal clues to vascular guidanceExperimental Cell Research, 2006
- Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesisExperimental Cell Research, 2005
- Oncogenes and tumor angiogenesis: The question of vascular ‘supply’ and vascular ‘demand’Seminars in Cancer Biology, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growthJournal of Cellular and Molecular Medicine, 2002
- Openings Through Endothelial Cells Associated with Increased Microvascular PermeabilityMicrocirculation, 1999
- Internal division of capillaries in rat skeletal muscle in response to chronic vasodilator treatment with α 1 -antagonist prazosinCell and tissue research, 1998
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996